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ABSTRACT
	 Bromodomain and extra terminal (BET) family proteins, which include BRD4, are readers of histone 
acetyl-lysines and key regulators of gene transcription. BRD4 inhibitors exert anti-tumor effects in various 
cancers, including hepatocellular carcinoma (HCC). We investigated the mechanism underlying the anti-
tumor effects of BRD4 inhibition in HCC. We first tested the effects of the BRD4 inhibitor JQ1 in a series of 9 
HCC cell lines and found that it strongly suppressed HCC cell proliferation by inducing cell cycle arrest and 
apoptosis. Gene expression microarray analysis revealed that JQ1 also induced marked changes in the gene 
expression profiles of HCC cells, and genes associated with cell cycle and apoptosis were significantly 
enriched among the affected genes. Notably, a number of cancer-related genes, including BCAT1, DDR1, 
GDF15, FANCD2, SENP1 and TYRO3, were strongly suppressed by JQ1 in HCC cells. We also confirmed BRD4 
bound within the promoter regions of these genes, which suggests they are targets of BRD4 in HCC cells. JQ1 
thus appears to exert its anti-tumor effects in HCC by suppressing multiple BRD4 target genes.
(Received Octover 3, 2018 and Accepted November 21, 2018)
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1.　Introduction
 Hepatocellular carcinoma (HCC) is one of the most 
commonly occurring cancers around the world, with 
approximately 782,000 new cases and 723,000 deaths 
annually 1）. HCC is associated with specific risk factors, 
including hepatitis B or C virus infection, high alcohol 
intake and nonalcoholic fatty liver disease (NAFLD), 
and many HCCs arise in the context of chronic 
hepatitis 2）. Despite recent improvements in the clinical 
treatments for HCC, it remains a dismal disease with 
a poor prognosis, and development of a new therapeutic 
strategy is much needed. 
 Recent studies have shown that a wide variety of 
epigenetic abnormalities, including aberrant DNA 
methylation and histone modifications, are involved in 
the development of cancer 3）. These epigenetic alterations 
are considered to be potential molecular targets for cancer 
diagnosis and promising therapies, and a number of 
drugs targeting epigenetic alterations have been 
developed 3）. The effectiveness of epigenetic therapy has 
been particularly evident in hematological malignancies, 
though recent studies are beginning to show its 
usefulness in solid tumors 3）. Epigenetic alterations are 
strongly implicated in the development and progression 
of HCC, making them potential therapeutic targets 4）. 
However, much about the clinical usefulness of epigenetic 
therapy in HCC remains unclear.
 Histone acetylation is a crucial epigenetic mechanism 
involved in regulating gene expression. Bromodomain and 
extra terminal (BET) family proteins recognize acetylated 
histones and play an essential role in transcriptional 
regulation. Members of BET family include BRD2, 
BRD3, BRD4, and BRDT 3）. Among them, BRD4 is well 
known to maintain and facilitate oncogenic transcription 
directly by recruiting transcriptional machinery or 
indirectly by binding to enhancers, thereby contributing 
to cancer cell proliferation and survival 5, 6）. The BET 
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inhibitor JQ1 competitively binds to acetyl-lysine 
recognition motifs and inhibits BRD4 7）. It also exerts 
strong anti-tumor effects in part through inhibition of 
MYC, which is well documented to be a major anti-tumor 
mechanism related to BRD4 inhibition 8）. However, 
BRD4 also targets other genes in cancer 9, 10）. In the 
context of HCC, oncogenes reportedly targeted by BRD4 
include MYC and E2F2, but the anti-tumor mechanism 
of BRD4 inhibition in HCC is not fully understood 11, 12）. 
In the present study, we aimed to clarify the anti-tumor 
mechanism of BRD4 inhibition in HCC. To that end, 
we assessed the effect of the BRD4 inhibitor JQ1 on gene 
expression profiles in a series of HCC cell lines, which 
enabled us to identify novel BRD4 target genes in 
HCC.
2.　Materials and methods
2.1 Cell lines and tissue samples
 HCC cell lines (JHH-4, Li-7, HepG2, Hep3B, HLE, 
HLF, huH-1, HuH-7 and PLC/PRF/5) were obtained 
and cultured as described previously 13）. Total RNA was 
isolated using TRIzol reagent (Thermo Fisher Scientific, 
Waltham, MA, USA). Total RNA from normal liver 
tissues from a healthy individual was purchased from 
BioChain (Hayward, CA, USA).
2.2 Cell viability assay
 HCC cells were seeded into 96-well plates to a 
density of 3000 cells/well in 100 µl of medium. Cells were 
then treated with 0.001 µM, 0.048 µM, 0.24 µM, 1.2 µM, 
6 µM or 30 µM JQ1 (Cayman Chemical Company, Ann 
Arbor, MI, USA). After incubation for 5 days, cell 
viability was assessed using a Cell Counting kit-8 (Dojindo, 
Kumamoto, Japan) according to the manufacturer's 
instructions.
2.3 Cell cycle and apoptosis assays
 For cell cycle analysis, HCC cells were treated for 
48 h with 1 µM JQ1 or DMSO, after which they were 
stained with propidium iodide (PI; Dojindo, Kumamoto, 
Japan) or with PI and an ApoScreen Annexin V 
Apoptosis Kit (Southern Biotech, Birmingham, AL, 
USA) according to the manufacturer's instructions. 
Flow cytometric analysis was then performed using a 
BD FACSCant II (BD Biosciences, Franklin Lakes, 
NJ, USA) and BD FACSDiva software (BD Biosciences). 
Data were analyzed using FlowJo software version 10 
(FlowJo LLC, Ashland, OR, USA).
2.4 Quantitative reverse transcription-PCR
 Single-stranded cDNA was prepared using 
PrimeScript RT Master Mix (Takara Bio Inc., Kusatsu, 
Japan). Quantitative reverse transcription-PCR (qRT-
PCR) was carried out using PowerUp SYBR Green 
Master Mix (Thermo Fisher Scientific) and a 7500 Fast 
Real-Time PCR system (Thermo Fisher Scientific). β
-actin (ACTB) was used as an endogenous control. 
Primer sequences are listed in Table 1.
2.5 Gene expression microarray analysis
 HCC cells were treated for 24 h with 1 µM JQ1 or 
DMSO, after which total RNA was extracted using 
TRIzol reagent (Thermo Fisher Scientific). Gene 
expression microarray analysis was performed as 
described previously 13）. Briefly, 100 ng of total RNA were 
labeled using a Low-input Quick Amp Labelling kit 
One-color (Agilent Technologies, Santa Clara, CA, USA), 
after which the synthesized cRNA was hybridized to a 
SurePrint G3 Human GE microarray v2 (G4851, Agilent 
Technologies). The microarray data were analyzed 
using GeneSpring GX version 13 (Agilent Technologies). 
2.6 Analysis using publically available datasets
 Gene expression and survival data of primary HCC 
patients in The Cancer Genome Atlas (TCGA) network 
study were obtained from University of California, Santa 
Cruz (UCSC) Cancer Browser (https://xena.ucsc.edu/) 14）. 
Data of acetylated histone H3 lysine 9 and 27 in HepG2 
cells were obtained from Encyclopedia of DNA Elements 
(ENCODE) database (https://genome.ucsc.edu/). 
2.7 RNA interference
 HCC cells (5×105 cells/well in 6-well plates) were 
transfected with 25 pmol of a Silencer Select siRNA 
targeting BRD4 (ID, s23901; Thermo Fisher Scientific) 
or a Silencer Select Negative Control (Thermo Fisher 
Scientific) using Lipofectamine RNAiMAX (Thermo 
Fisher Scientific) according to the manufacturer's 
instructions. After incubation for 48 h, cells were harvested 
and analyzed.
2.8 Chromatin immunoprecipitation
 Chromatin immunoprecipitation (ChIP) was performed 
using a ChIP-IT High Sensitivity Kit (Active Motif, 
Carlsbad, CA, USA) according to the manufacturer's 
instructions. Briefly, 1×107 cells were fixed, sonicated 
and immunoprecipitated using a rabbit anti-BRD4 
monoclonal antibody (#13440, Cell Signaling Technology, 
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Danvers, MA, USA) or control IgG. Input DNA and the 
immunoprecipitates were then subjected to quantita ¬ tive 
PCR analysis using PowerUp SYBR Green Master Mix 
(Thermo Fisher Scientific) according to the manufacturer's 
instructions. Primer sequences are listed in Table 1.
2.9 Statistical analysis
 Quantitative variables were analyzed using Student's 
t test. Survival was analyzed using the log-rank test 
for 2-group comparisons. Values of P < 0.05 (2 sided) were 
considered statistically significant. Statistical analyses 
were carried out using EZR version 1.32 (Saitama 
Medical Center, Jichi Medical University, Saitama, 
Japan) 15）.
3.　Results
3.1 Anti-tumor effects of BRD4 inhibition in HCC 
cell lines
 To evaluate the anti-tumor effects of BRD4 inhibition 
in HCC cells, we treated a series of 9 HCC cell lines 
with serial dilutions of JQ1 for 5 days and then 
performed cell viability assays. We found that JQ1 
dose dependently suppressed proliferation of all the 
HCC cells tested (Figure 1). HuH-7, Hep3B and HLE 
cells were highly sensitive to JQ1, with IC50 values of 
0.046, 0.048 and 0.076 µM, respectively (Figure 1A). 
Cell cycle analysis using flow cytometry revealed that 
treatment with JQ1 (1.0 µM for 48 h) led to increases 
Table 1. Sequences of the primers used in this study
　 Forward Reverse Product size
qRT-PCR
ACTB 5'-GCCAACCGCGAGAAGATGA-3' 5'-AGCACAGCCTGGATAGCAAC-3' 80 bp
BCAT1 5'-TTGGAACTGAGCCTTCTCTTGG-3' 5'-CACTGGGCTCAAGAGTACAAAG-3' 71 bp
BRD4 5'-CCGATTGATGTTCTCCAACTGC -3' 5'-TCTTGGCAAAGCGCATTTCG-3' 104 bp
DDR1 5'-AGGAGTTCTCCCGGAGCTAC-3' 5'-AAGGTCCTTCAGCACCACTC-3' 131 bp
E2F2 5'-ATCATGGAGCCCACAGCATC-3' 5'-GGCTGTCAGTAGCCTCCAA-3' 100 bp
FANCD2 5'-TGGGATTATTGGTGCTGTGACC-3' 5'-TGGCTCTCTCTTGGGTCAAAC-3' 83 bp
GDF15 5'-AGAGCTGGGAAGATTCGAACAC-3' 5'-AGATACGCAGGTGCAGGTG-3' 105 bp
MAPK3 5'-CATGAGAATGTCATCGGCATCC-3' 5'-GCAGATATGGTCATTGCTCAGC-3' 144 bp
MYC 5'-TTCTCTGAAAGGCTCTCCTTG-3' 5'-GTTGGTGAAGCTAACGTTGAG-3' 107 bp
NUAK1 5'-GACATGGTTCACATCAGACGAG-3' 5'-CCCTTTGCTGGCATATTCCATG-3' 129 bp
PAK1 5'-TCTAAACCTCTGCCTCCAAACC-3' 5'-AAATCTCTGGCCGCTCTTTC-3' 115 bp
SENP1 5'-AGAGGCGACATGTTAGTACAGC-3' 5'-AAATGTGTGGTGGGTTTGGC-3' 121 bp
TYRO3 5'-AAACAGCCTCCGGAGTGTATG-3' 5'-TGTTCTCCAGTTCCATTCGC-3' 146 bp
ChIP-qPCR
BCAT1 #1 5'-TCCGTTCCCAAAAGCGAATG-3' 5'-TTATATCCCCCGCAAACGTCTC-3' 141 bp
BCAT1 #2 5'-AGACGTTTGCGGGGGATATAAG -3' 5'-ATGTGTGCGTGAATCGAACC-3' 100 bp
BCAT1 #3 5'-CAGGAAAGCGCATTTACAGC -3' 5'-TCCCCTGCTTGTGAAGTTTG-3' 122 bp
DDR1 #1 5'-AGGAGCAAAGGTTGGTGGAG-3' 5'-CCAGAGAAGGGAGCAGAGC-3' 89 bp
DDR1 #2 5'-TGTCCTGGCCTCATTTTTGG -3' 5'-TCCCAACGGAGTGGAGTGG-3' 129 bp
FANCD2 #1 5'-ATGGGCGAGCTTCTCTTCAC-3' 5'-AGGCAATAAGCTGGGCTCAC-3' 124 bp
FANCD2 #2 5'-TCGGTGAGTAAGTGGAGCAATG -3' 5'-AGATGAGGAAGCCAAGGTTCG-3' 122 bp
FANCD2 #3 5'-AATCCCCACAGGTACCTTTCTG -3' 5'-AACACGTGCGATACCATCTG-3' 149 bp
GDF15 #1 5'-GCATGACACATCAAGGTTGC-3' 5'-TTTTGGTTGGGGTCAAAGGC-3' 98 bp
GDF15 #2 5'-AGATCCTCCCCCTAAATACACC -3' 5'-CGGACCGGCCTTTATAGTCC-3' 136 bp
MAPK3 #1 5'-CAGCTGAGACTCAAAATGGTGTC-3' 5'-TTATTGCACCACTACACTCCAG-3' 139 bp
MAPK3 #2 5'-CTCGGAGACTGTCCTCACC -3' 5'-TGGGCTGCCGCATACATTG-3' 89 bp
NUAK1 #1 5'-AGGCCTGGTGTTCGGTTAC-3' 5'-TTCTCCTGGACTCGGAGTTG-3' 108 bp
NUAK1 #2 5'-AAGAGATGGGGCTCTAAAGGC -3' 5'-CAAACGGGTTGCTCAGCAG-3' 141 bp
NUAK1 #3 5'-GTAAGGGTCAGGCAGGAAGG -3' 5'-GTCTGGTACATTGCACCACTTG-3' 144 bp
PAK1 #1 5'-TAACAAAGCACCACCGCATC-3' 5'-ACATGTCTGGCTGTGAGATCAC-3' 89 bp
PAK1 #2 5'-ACGCCTGGGATTACGTCATC-3' 5'-AAAGGCTGCACGGAAACAAC-3' 130 bp
SENP1 #1 5'-TGGGCTTTTTCGCTTTCTCG -3' 5'-AAACTGGAACGCAAGCAAGC-3' 136 bp
SENP1 #2 5'-TTTCCATGGCAGCTTTTCGC-3' 5'-AACACGAGATAGCCTGAGATCG-3' 105 bp
TYRO3 #1 5'-TGGGCTTTTTCGCTTTCTCG -3' 5'-AAACTGGAACGCAAGCAAGC-3' 136 bp
TYRO3 #2 5'-TTTTGAGGGAAGGCTCTGGAG-3' 5'-AAACCTGAGGATCCGGCTTG-3' 114 bp
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in G0+G1 phase and decreases in S and G2+M phases 
in the JQ1-sensitive HuH-7, HLE and Hep3B cells 
(representative results in Figure 1B). In addition, Annexin 
V staining assays showed that JQ1 induced apoptosis 
in HuH-7, HLE and Hep3B cells (representative results 
in Figure 1C). In contrast, induction of apoptosis or cell 
cycle arrest by JQ1 was minimal in less sensitive huH1 
and PLC/PRF/5 cells (data not shown). These results 
confirm the strong anti-tumor effect of JQ1 in HCC cells, 
while the effects were somewhat various among cell 
lines.
3.2 Effects of BRD4 inhibition on gene expression 
profiles in HCC
 We next sought to understand the mechanism 
underlying the anti-tumor effects of BRD4 inhibition in 
Figure 1. Anti-proliferative effects of BRD4 inhibition in HCC cells. (A) Cell viability assays using HCC cell lines treated for 5 days 
with the indicated concentrations of JQ1. IC50 values are shown on the right. (B,C) Results of cell cycle (B) and apoptosis (C) 
analyses using the indicated cell lines treated for 48 h with 1 µM JQ1. Representative results are shown on the left. Summarized 
results of 3 replications are shown on the right. Error bars represent SDs. **P < 0.01; ***P < 0.001.
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HCC cells. Because previous studies showed that MYC 
and E2F2 are targets of BRD4 in HCC cells (11, 12), 
we first performed qRT-PCR analysis to assess the 
effect of JQ1 on their expression in HCC cells. We 
tested 3 HCC cell lines, HuH-7, HLE and HepG2, 
because these cell lines were used in earlier reports 
and/or they were sensitive to JQ1 (11, 12). We found 
that treatment with JQ1 (0.5 µM, 1.0 µM or 2.0 µM) for 
6 to 24 h significantly suppressed MYC expression in 
all three cell lines tested. In HLE and HepG2 cells, 
however, MYC expression recovered within 48 h, despite 
continued treatment with JQ1 (Figure 2A). Expression 
of E2F2 was also strongly suppressed by JQ1 in all cell 
lines tested, and it continued to be downregulated after 
48 h of JQ1 treatment (Figure 2B). 
 To further clarify the effects of BRD4 inhibition 
Figure 2. Suppression of MYC and E2F2 by JQ1 in HCC cell lines. (A) Results of qRT-PCR analyses of MYC in the indicated HCC 
cell lines treated with the indicated concentrations of JQ1. (B) Results of qRT-PCR analyses of E2F2 in the indicated HCC cell lines 
treated with the indicated concentrations of JQ1. Results are normalized to ACTB expression. Shown are means of 3 replications; 
error bars represent SDs; *P < 0.05; **P < 0.01; ***P < 0.001.
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on gene expression profiles in HCC cells, we next 
treated the 9 HCC cell lines with or without 1 µM JQ1 for 
24 h and then performed a gene expression microarray 
analysis. The results showed that expression of 7112 
probe sets (5497 unique genes) were significantly altered 
by JQ1 treatment (t-test, P < 0.05), which suggests 
BRD4 inhibition dramatically affects gene expression 
profiles in HCC cells (Figure 3A). Gene ontology analysis 
suggested that genes associated with membranes and 
intracellular organelles are significantly enriched 
among the downregulated genes (2304 probe sets, 1868 
unique genes, Figure 3B). In addition, pathway analysis 
revealed that genes associated with cell cycle, apoptosis 
and cancer pathways were significantly enriched 
among the downregulated genes (Figure 3B). E2F2 
was significantly downregulated by JQ1 in 8 of the 9 HCC 
cell lines tested (Figure 3C), but MYC was downregulated 
to a lesser degree than E2F2 (Figure 3C). We also 
Figure 3. Effects of BRD4 inhibition on gene expression profiles in HCC cells. (A) Heat map showing expression of 7112 probe sets (5497 
genes) whose expression was altered by JQ1 treatment in the indicated HCC cell lines. Results are normalized to cells treated with 
DMSO. (B) Results of gene ontology (GO, upper) and pathway analyses (lower) of the downregulated genes in (A). RB, retinoblastoma. 
(C) Heat map showing microarray results for E2F2, MYC, BCL2L11 and MCL1. (D) Heat map showing microarray results for the 
indicated genes.
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observed that BCL2L11 and MCL1 were upregulated by 
JQ1 in multiple HCC cell lines, which is consistent with 
earlier reports (11, 16) (Figure 3C). 
3.3 Identification of novel targets of BRD4 in HCC 
cells
 To identify targets of BRD4 that could be involved in 
the anti-tumor effect of BRD4 inhibition, we isolated a 
Figure 4. Expression of candidate BRD4 target genes in primary HCC tissues. (A) Summaries of the relative expression levels of the indicated genes 
in primary HCC tumors (n = 377) and normal liver tissues (n = 59) in the TCGA dataset. **P < 0.01; ***P < 0.001; NS, not significant. (B) 
Kaplan-Meier curves showing the effects of expression of the indicated genes on survival of HCC patients in the TCGA dataset (n = 365). 
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list of genes suppressed by JQ1 in HCC cell lines (278 
probe sets, 226 unique genes) that satisfied more 
stringent criteria (> 2-fold, P < 0.05). Through comparison 
with publically available datasets for primary HCC 
from The Cancer Genome Atlas (TCGA), we selected for 
further analysis 7 genes (BCAT1, FANCD2, MAPK3, 
NUAK1, PAK1, SENP1 and TYRO3) whose expression 
levels were significantly higher in primary HCC 
tumors than in normal liver tissues (Figure 4A). Also 
selected were DDR1 and GDF15, which are reportedly 
associated with HCC development. Analysis of the 
associations between the expression levels of the 
selected genes and HCC patient prognosis revealed 
that elevated expression of BCAT1, DDR1, SENP1 and 
TYRO3 was associated with shorter overall survival 
(Figure 4B). Our microarray analysis confirmed that the 
selected 9 genes were significantly downregulated by 
JQ1 in HCC cell lines (Figure 3D).
 qRT-PCR revealed that BCAT1, DDR1, FANCD2, 
GDF15, SENP1 and TYRO3 are upregulated in multiple 
HCC cell lines as compared to normal liver tissue 
(Figure 5). We thus selected these genes for further 
analysis. qRT-PCR analysis performed to validate the 
microarray results revealed that expression of the 6 
genes was effectively suppressed by JQ1 in most of the 
HCC cell lines tested (Figure 6A). We next tried to confirm 
whether the suppressive effects on gene expression 
depend on direct inhibition of BRD4. To this end, we 
selected three HCC cell lines, HuH-7, HLE and HepG2, 
because these cell lines were used in earlier reports 
and/or they were sensitive to JQ1 (11, 12). We found that 
knocking down BRD4 using a specific siRNA led to 
decreased expression of these genes in the selected HCC 
cell lines, although degrees of downregulation were 
lesser than those by JQ1 (Figure 6B). 
 To determine whether these genes are direct targets 
of BRD4, we performed ChIP analysis using an anti-
BRD4 antibody. Using the ENCODE (Encyclopedia of 
DNA Elements) datasets for HepG2 cells prior to that 
analysis, we found that levels of acetylated histone H3 
Figure 5. Results of qRT-PCR analyses of candidate BRD4 target genes in normal liver tissue and HCC cell lines. Results are normalized to 
ACTB expression. Shown are means of 3 replications; error bars represent SDs.
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Figure 6. Inhibition of BRD4 suppresses expression of candidate BRD4 target genes in HCC cells. (A) Results of qRT-PCR analyses of the 
indicated genes in HCC cell lines treated for 24 h with DMSO or JQ1 (1 µM). (B) Results of qRT-PCR analyses of the indicated 
genes in HCC cell lines transfected with a control siRNA or a siRNA targeting BRD4. Results are normalized to ACTB expression. 
Shown are means of 3 replications; error bars represent SDs; *P < 0.05; **P < 0.01; ***P < 0.001.
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lysine 9 and 27 were elevated at the promoters and 
transcription start sites of the 6 genes (Figure 7). Further 
analysis of these regions using ChIP-qPCR revealed 
BRD4 to be significantly enriched in all the regions 
tested (Figure 8).
4.　Discussion
 In the present study, we first confirmed the anti-
tumor effects of BRD4 inhibition using a series of HCC 
cell lines. We found that treatment with the BRD4 
inhibitor JQ1 suppressed HCC cell proliferation by 
inducing cell cycle arrest and apoptosis, though the 
sensitivities to JQ1 varied among cell lines. The mechanism 
underlying the anti-tumor effect of BRD4 inhibition in 
HCC cells was investigated in several earlier studies. 
For instance, Hong et al. showed that E2F2 is a direct 
target of BRD4 and that the BRD4-E2F2 cell cycle 
circuit is an important therapeutic target in HCC 12）. 
We found that JQ1 strongly suppressed E2F2 expression 
in most of the HCC cell lines tested. 
 MYC is the most well-studied target of BRD4 in 
various types of cancer, though the effect of BRD4 
inhibition on MYC in HCC remains controversial. Li et al. 
showed in multiple HCC cell lines that JQ1 suppresses 
MYC in a dose and time dependent manner (11). However, 
Hong et al. observed no significant effect of JQ1 on MYC 
expression in HCC cell lines 12）. Our qRT-PCR analysis 
revealed that treatment with JQ1 rapidly (6 to 24 h) 
suppressed MYC expression in multiple HCC cell lines, 
but MYC expression then recovered with more prolonged 
treatment. Consistent with the qRT-PCR results, our 
microarray analysis also showed that treatment with 
1 µM JQ1 for 24 h only moderately suppressed MYC in 
HCC cell lines. These data may explain the earlier 
contradictory results for JQ1 effects on MYC expression. 
We also observed that JQ1 treatment led to upregulation 
of genes reportedly associated with the drug's effects. 
BCL2L11 (BIM) is a pro-apoptotic gene and its upregulation 
Figure 7. Histone acetylation status of candidate BRD4 target genes in HepG2 cells. ChIP-seq results of acetylated histone H3 lysine 9 
(H3K9ac) and H3K27ac were obtained from the ENCODE dataset.
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Figure 8. BRD4 binding to candidate target genes in HCC cells. (A,B) Summarized results of ChIP-qPCR analyses of the indicated genes in 
HepG2 (A) and HuH-7 cells (B). Regions analyzed are shown at the top, and locations relative to the transcription start site (TSS) 
are also indicated. Results are normalized to respective input DNAs. Shown are means of 3 replications; error bars represent SDs; 
*P < 0.05; **P < 0.01; ***P < 0.001.
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by JQ1 triggers apoptosis in HCC cells (11). MCL1 is 
also reportedly induced by JQ1 in HCC cells, though it 
antagonizes the JQ1-triggered anti-tumor effect 16）.
 To identify novel targets of BRD4 that could be 
associated with the anti-tumor effects of BRD4 inhibition 
in HCC cells, we performing a gene expression microarray 
analysis, which revealed that a number of genes with 
oncogenic properties are downregulated by JQ1 treatment. 
Branched-chain amino acid transaminase 1 (BCAT1, 
also known as ECA39) encodes the cytosolic form of the 
enzyme, which catabolizes branched-chain amino acids 
(BCAAs) 17）. Expression of BCAT1 is increased in HCC 
tissues, where it promotes cell proliferation, migration and 
invasion 18, 19）. One recent study showed that overexpression 
of BCAT1 in HCC may also induce circulating tumor cell 
release by triggering epithelial-mesenchymal transition, 
and that BCAT1 may be an important marker of HCC 
metastasis 20）. 
 Discoidin domain receptor 1 (DDR1) belongs to a 
receptor tyrosine kinase family  characterized by a 155-amino 
acid discoidin homology domain in its extracellular 
region 21）. In HCC, elevated DDR1 expression is associated 
with early recurrence and promotion of HCC cell migration 
and invasion via activation of matrix metalloproteinase-2 
(MMP-2) and MMP-9 22, 23）. Another study showed that 
miR-199a-5p targets DDR1, and that downregulation 
of miR-199a-5p is one of the mechanisms underlying 
DDR1 overexpression in HCC 24）. 
 Growth differentiation factor 15 (GDF15), also 
known as macrophage inhibitory cytokine-1 (MIC-1), is a 
member of the transforming growth factor-β (TGF-β) 
superfamily and is overexpressed in multiple tumor 
types 25）. GDF15 is induced in hepatocytes by hepatitis 
C virus infection, and serum GDF15 levels are elevated 
in patients with liver cirrhosis or HCC 26, 27）. Although 
genetic ablation of Gdf15 does not affect HCC development 
in mice, recent studies showed that GDF15 promotes 
proliferation, migration, invasion and metastasis by 
HCC cells 28-30）. Moreover, GDF15 secreted by HCC 
cells enhances tumor angiogenesis 30, 31）. These results 
suggest that GDF15 is involved in the pathogenesis of 
HCC and could be a diagnostic marker and a therapeutic 
target. 
 Fanconi anemia complementation group D2 (FANCD2) 
is a member of Fanconi anemia (FA) protein family. 
FA is a rare genetic disorder characterized by congenital 
abnormalities, progressive pancytopenia and increased 
cancer susceptibility 32）. Komatsu et al. reported that high 
FANCD2 expression is associated with poorer prognosis 
in HCC patients and that FANCD2 knockdown diminished 
the proliferation and invasiveness of HCC cells 33）. 
 SUMOylation, which entails conjugation of small 
ubiquitin-like modifier (SUMO) proteins to target 
substrates, is an important post-translational protein 
modification 34）. Specific SUMO protease 1 (SENP1) is 
essential for stabilization of hypoxia-inducible factor 1α 
(HIF-1α ) through de-conjugation of SUMO proteins 
(deSUMOylation) 35）. A recent study showed that hypoxia 
enhances the stemness of HCC cells by promoting 
HIF-1α deSUMOylation by SENP1, and that SENP1 
is a direct target of HIF-1/2α 36）. This suggests the existence 
of a positive feedback loop between SENP1 and HIF-1α . 
SENP1 also reportedly regulates hepatocyte growth 
factor (HGF)-induced migration and invasion by HCC 
cells 37）. 
 TYRO3 belongs to the TAM (TYRO3, AXL and 
MERTK) family of receptor tyrosine kinases 38）. Duan et al. 
recently reported that TYRO3 is frequently overexpressed 
in primary HCC, and that knocking down TYRP3 
suppresses proliferation, ERK phosphorylation and cyclin 
D1 expression in HCC cells 39）. TYRO3 is also reportedly a 
target of miR-7, which functions as a tumor suppressor 
in HCC 40）. TYRO3 promotes HCC cell proliferation, 
migration and invasion through activation of the PI3K/
AKT pathway, and its expression in HCC cells is markedly 
increased in cells exhibiting sorafenib resistance. Induction 
of miR-7 effectively overcomes sorafenib resistance by 
suppressing TYRO3, which suggests the miR-7/TYRO3 
axis could be a useful therapeutic target in sorafenib-
resistant HCC 40）.
 Using ChIP-qPCR analysis, we confirmed BRD4 
binding within the promoter and transcription start 
site regions of the genes we identified in this study. 
Taken together with the earlier reports summarized 
above, our results suggest that these genes are direct 
targets of BRD4 and that their suppression may 
contribute to the anti-tumor effect of BRD4 inhibition in 
HCC cells. However, there are several limitations to our 
study. It is well documented that the anti-tumor mechanism 
of BRD4 inhibition is attributable to the removal of 
BRD4 from super-enhancers, which regulate expression 
of key oncogenes, including MYC 6）. It is therefore possible 
that the candidate BRD4 target genes are regulated 
by enhancers located at genomic regions distant from 
the transcription start sites. Identification of such 
enhancer regions is challenging, and further genomic 
and epigenomic analyses to identify distant regulatory 
regions will be necessary to address this issue. Second, 
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although the HCC cell lines tested in this study exhibit 
different sensitivities to JQ1, we could not identify genes 
associated with JQ1 sensitivity. The candidate BRD4 
target genes we identified were suppressed by JQ1 in 
most of the HCC cell lines tested, irrespective of their 
sensitivity to JQ1. Third, we found that knockdown of 
BRD4 was less effective to suppress candidate BRD4 
target genes than JQ1, suggesting that the effect of 
JQ1 on these genes may be attributable to inhibition of 
other targets than BRD4.
 In summary, we show that BRD4 inhibition significantly 
affects gene expression profiles in HCC cells. Among the 
genes downregulated by BRD4 inhibition, we identified a 
series of novel BRD4 target genes. Our findings suggest 
that suppression of multiple genes with oncogenic 
function may contribute to the anti-tumor effect of 
BRD4 inhibition in HCC.
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　BRD4 を含む BET ファミリー蛋白質はアセチル化
ヒストンのリーダー蛋白質であり，転写調節において
重要な役割を担っている．BRD4 阻害剤は様々な悪
性腫瘍において抗腫瘍効果を示す事が報告されている．
今回我々は，肝細胞癌における BRD4 阻害の抗腫瘍
効果メカニズムの解明を目的とした．まず BRD4 阻
害剤 JQ1 の抗腫瘍効果を 9 種類の肝癌細胞株を用い
て検証した結果，増殖抑制，細胞周期停止，アポトー
シスの誘導が認められた．次に我々は，JQ1 が遺伝子
発現に与える影響をマイクロアレイによって解析した．
その結果，JQ1 が細胞周期やアポトーシス関連遺伝
子に強い影響を与えること，そして BCAT1，DDR1，
GDF15，FANCD2，SENP1，TYRO3 など複数の肝
細胞癌関連遺伝子の発現を抑制することを見いだした．
これらの遺伝子のプロモーター領域への BRD4 結合
が確認されたことから，これらは肝細胞癌における
BRD4 の標的遺伝子と考えられた．今回の結果から，
BRD4 阻害剤は複数の癌関連遺伝子を抑制すること
で，肝細胞癌に対する抗腫瘍効果を示すと考えられた．

